COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,627 Articles (22,913 medRxiv, 8,714 bioRxiv)

Most recent first Previous |  Page 553: Articles 5521-5530  | Next

Monitoring and responding to emerging infectious diseases in a university setting: A case study using COVID-19
Soda, K. J., Chen, X., Feinn, R., Hill, D.
10.1101/2023.01.13.23284515 — Posted: 2023-01-13
The COVID-19 antibody responses, isotypes and glycosylation: Why SARS-CoV-2 Spike protein complex binding of IgG3 is potentiated in some and immuno-pathologies manifest.
Iles, R. K.
10.1101/2023.01.13.23284524 — Posted: 2023-01-13
Data-driven Targeting of COVID-19 Vaccination Programs: An Analysis of the Evidence on Impact, Implementation, Ethics and Equity
McLaren, Z. M.
10.1101/2023.01.12.23284481 — Posted: 2023-01-13
Anthracyclines inhibit SARS-CoV-2 infection
Wang, Z., Pan, Q., Ma, L., Zhao, J., McIntosh, F., Liu, Z., Ding, S., Lin, R., Shan, C., Finzi, A., Liang, C.
10.1101/2023.01.10.523518 — Posted: 2023-01-13
Safety and Efficacy of Oral administrated Cepharathine in Non-hospitalized, asymptomatic or mild COVID-19 patients: A Double-blind, Randomized, Placebo-controlled Trial
Wei, J., Pan, S., Liu, S., Qian, B., Shen, Z., Zhang, Y., Bian, Y., ABuduaini, A., Dong, F., Zhang, X., Li, J., Yu, Y., Zhang, W., Wang, J., Zhai, W., Song, Q., Zheng, Y., Li, L., Pan, W., Yu, L., Zhang, Q., Zhang, N., Zheng, J., Yao, C., Li, H.
10.1101/2023.01.11.23284098 — Posted: 2023-01-12
The role of SARS-CoV-2 variants of concern in children and adolescents with COVID-19: a systematic review
Wiedenmann, M., Ipekci, A. M., Araujo Chaveron, L., Prajapati, N., Lam, Y. T., Alam, M. I., L'Huillier, A., Zhelyazkov, I., Heron, L., Low, N., Goutaki, M.
10.1101/2023.01.12.23284434 — Posted: 2023-01-12
Comparison of different isolation periods for preventing the spread of COVID-19: a rapid systematic review and a modelling study
Gao, Y., Zhao, Y., Zhang, X., Tian, J., Guyatt, G., Hao, Q.
10.1101/2023.01.12.23284479 — Posted: 2023-01-12
The natural tannins oligomeric proanthocyanidins and punicalagin are potent inhibitors of infection by SARS-CoV-2 in vitro
Chen, H.-F., Wang, W.-J., Chen, C.-Y., Chang, W.-C., Hsueh, P.-R., Peng, S.-L., Wu, C.-S., Chen, Y., Huang, H.-Y., Shen, W.-J., Wang, S.-C., Hung, M.-C.
10.1101/2023.01.12.523465 — Posted: 2023-01-12
Vectored Immunoprophylaxis and Treatment of SARS-CoV-2 Infection
Tada, T., Dcosta, B. M., Minnee, J., Landau, N. R.
10.1101/2023.01.11.523649 — Posted: 2023-01-12
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
Vaca, G. B., Meyer, M., Cadete, A., Hsiao, C. J., Golding, A., Jeon, A., Jacquinet, E., Azcue, E., Guan, C. M., Sanchez-Felix, X., Pietzsch, C. A., Mire, C. E., Hyde, M. A., Comeaux, M. E., Williams, J. M., Sung, J. C., Carfi, A., Edwards, D. K., Bukreyev, A., Bahl, K.
10.1101/2023.01.11.523616 — Posted: 2023-01-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).